H3 Biomedicine Inc
H3 Biomedicine Inc. is a privately held, uniquely structured oncology discovery enterprise. At H3, we seek to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue patient-based, genomics-driven, small molecule drugs, which represent the most promising current opportunity in cancer therapeutics.
At H3 Biomedicine, drug discovery starts with the patient. Leveraging deep expertise in the genetics of cancer to mine the large cache of publicly available cancer genomics data, our scientists work outward from genetically defined populations to identify new or confirm therapeutic targets. Our discovery teams then apply the latest chemical synthesis and cell-based screening methods to rapidly identify and develop libraries of small molecules that interact with those targets, as well as biomarkers to facilitate patient identification and clinical testing. This disciplined method promises to produce a steady stream of novel anti-cancer compounds against targets that have not yet been “druggable.”
For more information, please visit our web site at www.H3Biomedicine.com